Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.59 |
| ▸ | CES1 | P23141 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9341491 | 0.89 | CES2 (0.59) | CES2CES1L3MBTL1HTTKMT2A | |
| SCHEMBL13151879 | 0.86 | CES2 (0.61) | CES2CES1L3MBTL1HTTKMT2A | |
| SCHEMBL7804366 | 0.85 | CES2 (0.59) | CES2CES1L3MBTL1HTTKMT2A | |
| SCHEMBL1748151 | 0.80 | CES1 (0.63) | CES2CES1L3MBTL1HTTSNCA | |
| SCHEMBL9238566 | 0.78 | CES2 (0.50) | CES2CES1L3MBTL1KMT2AACKR3 | |
| SCHEMBL10832422 | 0.77 | CES2 (0.59) | CES2CES1L3MBTL1HTTKMT2A | |
| SCHEMBL7606342 | 0.77 | CES2 (0.53) | CES2CES1L3MBTL1HTTKMT2A | |
| SCHEMBL6945689 | 0.77 | CES2 (0.53) | CES2CES1L3MBTL1HTTKMT2A | |
| SCHEMBL6645293 | 0.76 | CES2 (0.49) | CES2CES1L3MBTL1KMT2ASNCA | |
| SCHEMBL11570 | 0.75 | CES2 (0.68) | CES2CES1L3MBTL1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265606-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-10-21 | — | — | EP | disclosed |
| US-8163921-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | CES2 87/4885CES1 34/4885L3MBTL1 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.